View on Pubmed.gov 32360420 | View on doi.org 10.1016/j.cytog... | View the free full text Full text
Cytokine storm intervention in the early stages of COVID-19 pneumonia.
- Department of Endocrinology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.
- Department of Nephrology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.
- Department of Hematology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.
- Translational Medicine Center, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.
- Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine. Nanjing, Jiangsu, China.
- Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Respiratory Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
- Translational Medicine Center, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China. Electronic address: wj6373@hotmail.com.
- Department of Endocrinology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China. Electronic address: wap454hospital@163.com.
Abstract
Clinical intervention in patients with corona virus disease 2019 (COVID-19) has demonstrated a strong upregulation of cytokine production in patients who are critically ill with SARS-CoV2-induced pneumonia. In a retrospective study of 41 patients with COVID-19, most patients with SARS-CoV-2 infection developed mild symptoms, whereas some patients later developed aggravated disease symptoms, and eventually passed away because of multiple organ dysfunction syndrome (MODS), as a consequence of a severe cytokine storm. Guidelines for the diagnosis and treatment of SARS-CoV-2 infected pneumonia were first published January 30, 2020; these guidelines recommended for the first time that cytokine monitoring should be applied in severely ill patients to reduce pneumonia related mortality. The cytokine storm observed in COVID-19 illness is also an important component of mortality in other viral diseases, including SARS, MERS and influenza. In view of the severe morbidity and mortality of COVID-19 pneumonia, we review the current understanding of treatment of human coronavirus infections from the perspective of a dysregulated cytokine and immune response.
References
Respirology. 2006 Nov;11(6):715-22
J Immunother Cancer. 2018 Jun 15;6(1):56
Cell. 2011 Sep 16;146(6):980-91
Immunotherapy. 2016 Jul;8(8):959-70
Cited by 532 citations (total)
Journal Article
Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway.
Electronic publication date April 15, 2021
Andrea R Daamen [...] Peter E Lipsky et al.
SARS-CoV2 is a previously uncharacterized coronavirus and causative agent of the COVID-19 pandemic. The host response to SARS-CoV2 has not...
Journal Article Research Support, Non-U.S. Gov't
Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
Electronic publication date June 25, 2021
Zhenyan Wang [...] Hongzhou Lu et al.
Dysregulation of immune response was observed in COVID-19 patients. Thymosin alpha 1 (Tα1) is used in the management of COVID-19,...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •
Copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.